Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia Corporation (Nasdaq: LQDA) disclosed in an 8-K that its wholly owned subsidiary, Liquidia Technologies, Inc., entered into an Indenture of Lease on 16 June 2025 with King Combs LLC for a new manufacturing facility in Morrisville, NC. The agreement covers 70,131 rentable square feet in Pathway Triangle Building 1 and runs from execution through 1 November 2036—a term of roughly 11 years and 5 months.
Key economic terms begin on the “Term Commencement Date” of 1 May 2026. Base rent will start at $260,069.13 per month (≈ $3.12 million annually) for the first 12-month period and will escalate 3.0 % each subsequent year. The company benefits from a six-month rent abatement after the commencement date but will assume responsibility for operating expenses thereafter.
The lease grants Liquidia (i) two 5-year extension options with 12-18 months’ notice and (ii) a one-time right of first offer on contiguous space, enhancing long-term flexibility. The filing states that the lease contains customary representations, warranties and covenants, and the full document will be filed with the forthcoming Form 10-Q for the quarter ending 30 June 2025.
For investors, the lease signals a significant capacity expansion ahead of expected commercial needs but also introduces a long-term fixed cost structure beginning in FY 2026.